The FDA has approved a new drug application for a long-acting version of glycoramer acetate.

Published Date: 10 Aug 2023

Treatment with GA Depot reduced the annualized relapse rate, the primary end point, and other secondary outcomes of T1 and T2 hyperintense lesions statistically significantly in the supporting phase 3 study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Psychedelic Therapy Tied to Reduced Depression, Anxiety.

2.

New drug resistance mechanism in melanoma leptomeningeal disease revealed by study.

3.

Research finds stark disparities in treatment and survival time for people with pancreatic cancer

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Relationship-building key to addressing oncologist shortages in rural care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot